Loading…
TBPH
Theravance Biopharma, Inc.
NASDAQ· Healthcare· Biotechnology
$17.05+0.06%
Key metrics
- Market cap
- $885.21M
- P/E
- 16.4x
- Forward P/E
- 13.4x
- P/B
- 3.1x
- Dividend yield
- —
- EPS
- $1.04
- ROE
- 20.91%
- Profit margin
- 51.58%
- Revenue growth
- -20.90%
- Beta
- 0.25
- 52-week high
- $21.03
- 52-week low
- $13.08
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
- 90
- South San Francisco, United States
Company description provided by Yahoo Finance.